Viewray Inc (NASDAQ:VRAY) Receives Average Rating of “Buy” from Analysts

Shares of Viewray Inc (NASDAQ:VRAY) have earned a consensus recommendation of “Buy” from the fourteen research firms that are currently covering the company, Marketbeat.com reports. Three analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $13.30.

VRAY has been the topic of a number of research analyst reports. BidaskClub raised shares of Viewray from a “sell” rating to a “hold” rating in a research report on Thursday, May 30th. ValuEngine raised shares of Viewray from a “hold” rating to a “buy” rating in a research report on Saturday, May 4th. Zacks Investment Research downgraded shares of Viewray from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, March 20th. B. Riley reissued a “buy” rating and set a $12.00 price objective (down from $13.75) on shares of Viewray in a research report on Monday, March 11th. Finally, Cantor Fitzgerald set a $13.00 price objective on shares of Viewray and gave the company a “buy” rating in a research report on Tuesday, May 28th.

Several large investors have recently added to or reduced their stakes in VRAY. Rhumbline Advisers raised its stake in shares of Viewray by 64.2% in the fourth quarter. Rhumbline Advisers now owns 77,647 shares of the company’s stock valued at $471,000 after acquiring an additional 30,364 shares during the last quarter. Prudential Financial Inc. raised its stake in shares of Viewray by 33.0% in the fourth quarter. Prudential Financial Inc. now owns 452,600 shares of the company’s stock valued at $2,518,000 after acquiring an additional 112,380 shares during the last quarter. Pearl River Capital LLC bought a new position in shares of Viewray in the fourth quarter valued at approximately $28,000. BlackRock Inc. raised its stake in shares of Viewray by 9.6% in the fourth quarter. BlackRock Inc. now owns 4,932,420 shares of the company’s stock valued at $29,940,000 after acquiring an additional 431,375 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its stake in shares of Viewray by 1.5% in the fourth quarter. Bank of New York Mellon Corp now owns 287,327 shares of the company’s stock valued at $1,744,000 after acquiring an additional 4,310 shares during the last quarter.

Viewray stock traded up $0.05 during mid-day trading on Tuesday, reaching $8.66. 7,008 shares of the company traded hands, compared to its average volume of 667,984. The company has a debt-to-equity ratio of 0.47, a current ratio of 4.28 and a quick ratio of 3.21. The stock’s 50 day moving average price is $8.56. The stock has a market capitalization of $834.74 million, a price-to-earnings ratio of -8.83 and a beta of 0.81. Viewray has a 52-week low of $4.86 and a 52-week high of $13.21.

Viewray (NASDAQ:VRAY) last issued its quarterly earnings data on Thursday, May 2nd. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.22) by ($0.12). The company had revenue of $20.30 million for the quarter, compared to analysts’ expectations of $20.40 million. Viewray had a negative net margin of 139.82% and a negative return on equity of 71.16%. The firm’s revenue for the quarter was down 22.5% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.11) earnings per share. As a group, analysts anticipate that Viewray will post -1 EPS for the current fiscal year.

About Viewray

ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.

Further Reading: Discount Rate

Analyst Recommendations for Viewray (NASDAQ:VRAY)

Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply